Want to see SCPX full AI Analyst Report?
SCPX Stock Chart & Stats
$0.02
-$0.05(-12.22%)
At close: 4:00 PM EST
$0.02
-$0.05(-12.22%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.15
Previous CloseN/A
Volume714.61K
Average Volume (3M)5.55K
Market Cap
$67.26K
Enterprise Value$17.55M
Total Cash (Recent Filing)$600.79K
Total Debt (Recent Filing)$18.12M
Price to Earnings (P/E)―
Beta-7.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding61,142,710
10 Day Avg. Volume3,056
30 Day Avg. Volume5,554
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.13
P/FCF Ratio-0.03
Enterprise Value/Market Cap260.92
Enterprise Value/Revenue4.66
Enterprise Value/Gross Profit47.75
Enterprise Value/Ebitda-0.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelScorpius operates across technology, real estate and renewable energy and earns fees, dividends and capital gains. This multi‑stream model reduces reliance on a single market cycle and gives management flexibility to reallocate capital to higher-growth portfolio areas over the next 2–6 months and beyond.
Positive Stockholders' EquityDespite pressures, the balance sheet still shows positive equity which provides a foundational cushion for creditors and a basis for restructuring or capital raises. That residual equity supports continuity of operations and preserves optionality for longer-term recovery or strategic transactions.
Management Alignment Via Insider FinancingA CEO‑controlled entity extending a convertible note signals insider willingness to support liquidity and align incentives. Structural insider funding can stabilize near‑term financing gaps and indicate management confidence in the business plan, strengthening governance alignment over the medium term.
Bears Say
Very High LeverageA 4.53 debt‑to‑equity ratio indicates substantial leverage that elevates refinancing, interest and covenant risk. High structural leverage limits strategic flexibility, increases default probability if cash flow remains weak, and magnifies losses to equity holders during prolonged revenue weakness.
Persistent Negative Cash FlowOngoing negative operating and free cash flow means the business cannot self‑fund growth or debt service and must rely on external financing. Structurally, this raises dilution or creditor control risks, constrains investment in portfolio companies, and undermines sustainable margin recovery prospects.
Defaults And Asset Sale RiskPublic disposition notice and defaults on secured notes threaten sale of pledged assets, which would permanently remove income‑generating holdings and advisory/management fee base. Asset loss would erode structural revenue capacity and impair the firm’s ability to rebuild capital and maintain strategic investments.
Scorpius Holdings News
SCPX FAQ
What was Scorpius Holdings’s price range in the past 12 months?
Scorpius Holdings lowest stock price was <$0.01 and its highest was $0.15 in the past 12 months.
What is Scorpius Holdings’s market cap?
Scorpius Holdings’s market cap is $67.26K.
When is Scorpius Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scorpius Holdings’s earnings last quarter?
Currently, no data Available
Is Scorpius Holdings overvalued?
According to Wall Street analysts Scorpius Holdings’s price is currently Overvalued.
Does Scorpius Holdings pay dividends?
Scorpius Holdings does not currently pay dividends.
What is Scorpius Holdings’s EPS estimate?
Scorpius Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scorpius Holdings have?
Scorpius Holdings has 61,142,710 shares outstanding.
What happened to Scorpius Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scorpius Holdings?
Currently, no hedge funds are holding shares in SCPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scorpius Holdings
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company serves the biotechnology and biopharmaceutical industries. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in San Antonio, Texas.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.02% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---